Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Live Nation Entertainment, Inc. (LYV) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Live Nation Entertainment (LYV) trades at $168.84, down 0.47% on the day, with a neutral technical signal. The stock shows strong analyst support with an 86.96% buy rating and a $208.64 consensus price target, implying significant upside. Recent Q2 2026 earnings beat expectations with EPS of $1.05 versus $0.66 expected, driven by robust fan attendance and record deferred revenue. However, valuation metrics remain elevated with a P/E of 117.49 and P/B of 484.76, while profitability is thin with a net income margin of 0.51%.

The outlook is cautiously optimistic given strong demand for live events and strategic expansions, but high debt levels, regulatory scrutiny, and execution risks pose challenges. Revenue growth is projected to reach $26.3 billion in 2026, though net profit margins are expected to compress to 0.51%. Investors should weigh the bullish analyst sentiment against the stock's rich valuation and operational headwinds.